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We thank Professor Legemate for his comments
regarding the paper by Miller et al. but feel we must
respond to his criticism of the ESVS’s and the EJVES’s
decision to accept the paper, respectvely, for presen-
tation and publication. With regard to the ESVS
meeting, each submitted abstract is scored blindly by
up to six people who are either members of the EJVES
Editorial Board or EJVES reviewers with a good ‘track
record’. As Miller’s abstract was scored among the top
35 submissions, it was accepted for oral presentation.
The degree to which an abstract reflects the accom-
panying paper varies as does the skill of those that
write the abstracts. However, I question whether a
more elaborate process, perhaps involving submission
of an extended abstract or the full paper, is actually
feasible, when picking out the approximately the top
10% for presentation. Concerning acceptance for the
journal of papers presented at annual meeting, they
are sent to three reviewers the same as any other paper
submitted for the journal. The explicit critique raised
by Prof. Legemate on the use of historic data and the
lack of details regarding survival data, was also raised
by the reviewers. The paper was accepted upon
revision, as I felt data represented the best available.
Here I would like to emphasise, that the decision of
accepting a paper for the journal, is with the editor
alone.
Neither the board nor the reviewers decide—they
advise.
I thank Prof. Legemate for drawing the attention to
these selection processes and excuse the delayed
response.T.V. Schroeder
Department of Vascular Surgery RK, Rigshospitalet 3111,
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Prof. Legemate1 identifies the use of remote historical
controls, whose characteristics are divergent in several
ways from our population, as a fundamental meth-
odological flaw, which renders our findings ‘both
misleading and meaningless’. We considered the
issues of historicity and match at length before we
submitted the abstract, and we debated this point with
commentators from the audience in Dublin and with
reviewers of the manuscript in the publication process.
We freely admit that the match with our cohort is less
than ideal, but we reiterate our point that the study of
Bickerstaff2 and colleagues represents the best evi-
dence we will ever have about the natural history of
thoracic/thoracoabdominal aortic aneurysm.
Fundamentally, Prof. Legemate’s criticism is about
quality of evidence, and it is based on the generally
accepted evidence-based medicine doctrine that clini-
cal trials represent the ultimate in clinical research
evidence. This is generally true, but is not so in this
case.
Watchful waiting clinical trials in vascular surgery
are different than the kinds of clinical trials that
evidence-based guidelines hold in highest esteem. The
difference is that the natural history of aortic
aneurysms is widely enough understood that equi-
poise is disrupted when aneurysms reach a certain
threshold, and surgical treatment—the treatment
being studied—is extended to patients in the non-
surgical group. That is to say, vascular surgery trials
are never run out to the bitter end (e.g. Lederle3).
Crossover triggers involve aneurysm size and rate of
expansion, which have been shown to increase risk of
rupture, and the crossovers are used for ethical, rather
than scientific, reasons. How have size and rate of
expansion been shown to increase risk? By observa-
tional natural history studies, such as the one we used
for our comparison. Therefore, we have clinical
trials—which reside at the top of the evidence
hierarchy—that have crossover rules based on
‘impure’ observational data. It is a peculiar irony
that, when we compute number needed to treat using
the kind of data that force crossover to surgery in
clinical trials, we are taken to task for not using data
from clinical trials!Eur J Vasc Endovasc Surg Vol 30, September 2005
Correspondence332In the strictest sense, crossover to surgery in these
trials should be considered a failure of medical
therapy. If trials such as the VA study estimated
event-free survival following initial treatment, the
5-year failure rate for medical therapy would be
greater than 70%.3 Yet the trials are presented as
straightforward intent-to-treat designs, and consider
crossover to be an incidental occurrence rather than a
treatment failure. What we have learned more than
anything is that small aneurysms follow the same
trajectory as large ones. Only the rate of expansion is
different. The vast majority of them get worse, and
they have been shown (in clinical trials) not to respond
at all to medical management.4
Clinical trials, therefore, are not the appropriate best
evidence for outcome in this paradigm, because
clinical trials are not allowed to proceed to outcome.
Watchful waiting clinical trials are informed by the
observational data that underlie their conversion
rules. In this particular situation, it is an appeal to
clinical trials as the highest standard of evidence for
outcome, rather than the use of scrupulously gathered
population-based observational data, which is ‘mis-
leading and meaningless’.
Prof. Legemate’s denunciation of our article as
something that should never have been published
underscores the importance of not allowing evidence-
based doctrine to become dogma. Rather, challenges to
dogmatic thinking are exactly the reason why
controversial material must be published. We should
resist the temptation to cut every cookie mindlessly
into the same shape, but instead should think about
what study designs mean. Randomized clinical trials
are wonderful tools most of the time, and it is tempting
to argue that no observational data are ever pure
enough to inform clinical practice. But uncritical
adherence to any kind of guidelines, evidence-based
or otherwise, is a recipe for bad practice. Clinical trials
only make sense in a context in which their findings
can be applied meaningfully to the actual clinical
situation. Evaluating the effect of thoracoabdominal
aortic repair on survival compared to the natural
history of the disease is not—and will never be—one
of those contexts.
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We found the paper by Hobbs and colleagues
interesting. It provides yet more data on the risks of
peripheral vascular surgery. We have some comments
to make which might however temper their con-
clusions. The authors conclude that over a third of
their patients that underwent bypass surgery for
critical limb ischaemia sustained silent myocardial
injury. Their conclusion is based upon their findings of
elevated cardiac troponin (cTnI). They also assert that
CK-MB and ECG significantly underestimate the
incidence of myocardial injury.
Cardiac troponin is currently the preferred bio-
marker of acute myocardial infraction (MI1).1 Unfor-
tunately, elevation of cTnI can be detected in a variety
of conditions other than myocardial ischaemia.2 The
authors did not appear to exclude patients with
known causes of cTnI elevation, such as acute
coronary syndrome, myopericarditis, cardiomyopa-
thy, pulmonary embolism, heterophile antibodies,
trauma and dialysis. Indeed, recent evidence indicates
that rhabdomyolysis patients may have raised cTnI.3
Causes of rhabdomyolysis include post-operative,
